The hepatic endothelial carcinogen riddelliine induces endothelial apoptosis, mitosis, S phase, and p53 and hepatocytic vascular endothelial growth factor expression after short-term exposure

Toxicol Appl Pharmacol. 2002 Nov 1;184(3):153-64. doi: 10.1006/taap.2002.9485.

Abstract

Riddelliineis a naturally occurring pyrrolizidine alkaloid found in certain poisonous rangeland plants of the western United States. In National Toxicology Program 2-year studies, riddelliine induced high incidences of hemangiosarcoma in the liver of F344/N rats (both sexes) and B6C3F1 mice (males). To understand this pathogenesis, we tested short-term effects of riddelliine. Three groups (control; 1.0 mg/kg/day, high dose used in the 2-year study; and 2.5 mg/kg/day) of seven male F344/N rats per group were terminated after 8 consecutive doses and 30 doses (6 weeks, excluding weekends). Serum vascular endothelial growth factor (VEGF), histological, immunohistochemical [factor VIII-related antigen/von Willebrand factor (fVIII-ra/vWf)], VEGF, VEGF receptor-2 (VEGFR2), glutathione S-transferase-pi, S-phase (BrdU), p53, apoptosis, and ultrastructural evaluations were performed on the liver. Following 8 doses of 1.0 and 2.5 mg/kg/day, increased numbers of apoptotic and S-phase nuclei appeared in hepatocytes and endothelial cells. Following 30 doses of 1.0 and 2.5 mg/kg/day, hepatocytes exhibited reduced mitosis, fewer S-phase nuclei, increased hypertrophy, and fatty degeneration, while endothelial cells showed karyomegaly, cytomegaly, decreased apoptosis, more S-phase nuclei, and p53 positivity. Hepatocytes of treated animals expressed higher VEGF immunopositivity. That altered endothelial cells were fVIII-ra/vWf and VEGFR2 positive confirmed their identity. These changes may have promoted hemangiosarcoma development upon long-term exposure through endothelial adduct formation, apoptosis, proliferation of endothelial cells having undamaged and/or damaged DNA, and mutation. Endothelial proliferation may also have been promoted through endothelial arrest at S phase, which was associated with endothelial karyo- and cytomegaly, resulting in hepatocytic hypoxia, triggering VEGF induction.

MeSH terms

  • Administration, Oral
  • Animals
  • Apoptosis / drug effects*
  • Bromodeoxyuridine / metabolism
  • Carcinogens / administration & dosage
  • Carcinogens / toxicity*
  • Dose-Response Relationship, Drug
  • Endothelial Growth Factors / blood
  • Hepatocytes / drug effects
  • Hepatocytes / metabolism
  • Hepatocytes / pathology
  • Immunoenzyme Techniques
  • Intercellular Signaling Peptides and Proteins / blood
  • Kupffer Cells / drug effects*
  • Kupffer Cells / metabolism
  • Kupffer Cells / pathology
  • Liver / drug effects*
  • Liver / metabolism
  • Liver / pathology
  • Lymphokines / blood
  • Male
  • Mitosis
  • Pyrrolizidine Alkaloids / administration & dosage
  • Pyrrolizidine Alkaloids / toxicity*
  • Rats
  • Rats, Inbred F344
  • S Phase / drug effects
  • Tumor Suppressor Protein p53 / metabolism
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • Vascular Endothelial Growth Factors
  • von Willebrand Factor / metabolism

Substances

  • Carcinogens
  • Endothelial Growth Factors
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • Pyrrolizidine Alkaloids
  • Tumor Suppressor Protein p53
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • von Willebrand Factor
  • riddelliine
  • Vascular Endothelial Growth Factor Receptor-2
  • Bromodeoxyuridine